Paediatric cancers
Abstracts from the 2026 meetings whose titles name children, adolescents or a childhood cancer, and the FDA list of molecular targets relevant to paediatric cancer. None of the five meetings has a single paediatric category that covers everything (ESMO 2026 lists 54 abstract categories and none is paediatric), so these are found by keyword across categories.
Incentives and obligations
FDA, content current as of 2026-04-29: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” FDA page
Each target page has a panel for its drugs: EU paediatric investigation plans and waivers, EU orphan designations, EU authorisation, FDA pediatric oncology approvals and registered studies that take children. Being on FDA's pediatric target list alone neither requires nor waives a pediatric study. Voucher sale prices are not shown as figures.
SITC Annual Meeting 2026
0 abstracts with a paediatric term in the title, live from Crossref 2026-11-11 15:09 UTC (keyword search, not exhaustive).
ESMO Congress 2026
1 abstract found by Parallel web research on 2026-11-11 and verified: 1 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- 4457PPoster
ASCO Annual Meeting 2026
14 abstracts with a paediatric term in the title, live from Crossref 2026-11-11 15:09 UTC (keyword search, not exhaustive).
- 9593Incidence and survival rates in pediatric and adolescent melanoma in the United States, 2001-2022.Maimoona Maheen, Aqiba Malik, Mehak Ruqia
- 10002Targeting metastatic sites with radiation and outcomes in high-risk pediatric rhabdomyosarcoma.Rachel Mendelson, Andrew Davidoff, Sara Helmig, Yimei Li et al.
- 10012Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs).Yizhuo Zhang, YI Zhang, Suying Lu, Weiling Zhang et al.
- 10027Peptide receptor radionuclide therapy with 177 Lu-DOTATATE in pediatric, adolescent, and young adult neuroendocrine tumors: A single-center experience from Bambino Gesù Children’s Hospital.Maria Debora De Pasquale, Evelina Miele, Aurora Castellano, Milena Pizzoferro et al.
- 10052Effects of delayed sodium thiosulfate on cisplatin-induced ototoxicity in pediatric and adolescent patients with cancer: Results from the Japanese Children’s Cancer Group STS-J01 study.Eiso Hiyama, Isamu Saeki, Eriko Uchida, Makiko Mori et al.
- 10056Development and early implementation of a statewide comprehensive childhood cancer network to support pediatric oncology care and research.Chris Hagemeyer, Nicole De Lara Puente, Jennifer McCafferty Fernandez
- 11518Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.Julia Lynne Glade Bender, Joseph Gerald Pressey, Lars M. Wagner, AeRang Kim et al.
- 11525Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.Hui Li, Kai-Li Pan, Wanliang Wu, Jing Li et al.
- E15125Evaluating the efficacy and mechanisms of action of seriniquinone against pediatric neuroblastoma.Peter E. Zage, Sriprada Kattamuri, Erin Yamaoka, Disha Surana et al.
- E18062Comparison of different induction chemotherapy regimens in pediatric and adolescent patients with locally advanced nasopharyngeal carcinoma.Ruiling Xie, Ye-Hao Zou, Zi-Xuan Chen, Ling-Ling Zhang et al.
- E18102Trends in pediatric and adolescent thyroid carcinoma incidence and survival in the United States, 2001-2022.Maimoona Maheen, Mehak Ruqia, Aqiba Malik
- E22005Post-operative neurologic outcomes in children with WNT-medulloblastoma.Daniel Bishay, Jennifer Cotter, Therry Malone, Mark Krieger et al.
- E22006Prognosis of mediastinal lymph node metastases in pediatric patients with osteosarcoma and lung metastases.Lee Ann Santore, Avantika Narasimhan, Peter Schoettler, Wendy A. Allen-Rhoades et al.
- TPS10057A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma.Emily K. Slotkin, Leo Mascarenhas, Kelly Bailey, Jeremy Howard Lewin et al.
AACR Annual Meeting 2026
13 abstracts with a paediatric term in the title, live from Crossref 2026-11-11 15:09 UTC (keyword search, not exhaustive).
- 628Investigating the role of BRCA2 in the development of pediatric rhabdomyosarcoma.Phillip Adam Weinstein, Elif Asik, Pagna Sok, Cem Ozdemir et al.
- 1161Comprehensive pediatric biobanking and model development in the Beat Childhood Cancer Research ConsortiumDivya Gandra, Katherine McClain, Meenakshi Shukla, Mohammad Haque et al.
- 1167The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of pediatric medulloblastoma patient-derived orthotopic xenograft mouse models.Xin (Alice) Zhai, Zilu Huang, Milagros Suarez Palacios, Tongchao Jiang et al.
- 1257Synergistic inhibition of PARP and ATM leads to unresolved DNA damage and cohesin-mediated collapse in pediatric osteosarcoma.Janeala Morsby, Sona Kocinsky, Estevez Prado Daniel, John Harper et al.
- 2248Inhibition of the mitochondrial antioxidant response blocks ex vivo lung colonization in pediatric osteosarcoma.Elli Maria Tiliakou, Michael Lizardo, Yue-Zhou Huang, Taras Shyp et al.
- 2704NCI’s childhood cancer data initiative: Advancing pediatric cancer research.Subhashini Jagu, Jaime Guidry Auvil, Mark Cunningham, Bahar Sayoldin et al.
- 3486Elucidating the role of ecDNA in treatment resistance and immune evasion within pediatric medulloblastomaMeenakshi Singhal, Joy Ku, Kun Wang, Rohit Bhargava
- 3502Loss of histone 3 lysine 9 trimethylation drives recurrence in high-risk pediatric medulloblastomaJohn DeSisto, Andrew M. Donson, Bethany Veo, Rajeev Vibhakar
- 4027Co-targeting GPC2 and B7-H3 with CAR T cells achieves durable responses in preclinical high-risk neuroblastoma and medulloblastoma modelsPatrick M. Schürch, Benjamin Draper, Vincent P. Zecchino, Hehai Pan et al.
- 7805Development of a GFRA2-targeting antibody drug conjugate for neuroblastoma (NB), and Ewing sarcoma (EWS)Amber K. Hamilton, Seungmin Shin, Raphael D. Lopez, Nicholas Hartnett et al.
- 7882Bridging data gaps in pediatric osteosarcoma: The first registry-based analysis of Puerto Rican casesMiaSara Pérez Salvá, Rocio Krystal Rivera-Valentin, Celinés Rodriguez, Liliana Marie Castro-Jimenez
- 7885Defining genome-wide cfDNA methylation landscapes in pediatric and adolescent and young adult (AYA) bone and soft-tissue sarcomasLilli J. Greiner, Roman O. Kowalchuk, Jeff Szymanski, Pradeep S. Chauhan et al.
- CT180
ASH Annual Meeting 2026
Not indexed in Crossref yet and no verified paediatric pull has been made for this meeting.
FDA Pediatric Relevant Molecular Target List
163 gene targets from the FDA's list, retrieved 2026-11-11. Version: Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01). They are flagged on every indication's Targets tab. 47 entries that are not a single gene are listed by the FDA's own name below.
Not mapped to a single gene: ETS gene fusions; EWSR1-FLI1; FGFR; Gamma secretase; Histone H3; mTORC1, mTORC2; Neoantigens; NF-kappa-B; NTRK; NUTM1 gene fusions; PARP; PAX-FOXO1; PML-RARA; RAS; SYT-SSX; CRBN [cereblon E3 ubiquitin ligase]; EGFRvIII (EGFR variant III); GD2 (disialoganglioside); VEGF; VEGFR; AKT; Asparagine; BCL2 family members (BCL2, BCL2L1, MCL1, BCL2A1, BAK1, BAX); BET bromodomain family; BMPR; CK1 (casein Kinase 1); CK2 (casein kinase 2); CREBBP/EP300; DNA (alkylators); DNA-PK; DNMT (DNA methyl transferase); GSK3; HDAC; Hippo pathway (YAP1, WWTR1 (TAZ), TEADs); HSP90; Inhibitor of apoptosis (IAP) proteins; NEDD8 activating enzyme (NAE); PKA (protein kinase A); PKC (protein kinase C); Proteasome; PTPN (protein tyrosine phosphatase); RNA polymerase (RNApol) I; SSTR (somatostatin receptor); SWI/SNF; TGF-beta; TOP1, TOP2 (DNA topoisomerase I/II); Tubulin.